Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 165.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 735,217 shares of the company's stock after acquiring an additional 457,940 shares during the period. Charles Schwab Investment Management Inc. owned 0.64% of Applied Therapeutics worth $6,249,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in APLT. Victory Capital Management Inc. acquired a new position in Applied Therapeutics in the 2nd quarter valued at about $54,000. Principal Financial Group Inc. acquired a new position in Applied Therapeutics in the 2nd quarter valued at about $54,000. SG Americas Securities LLC acquired a new position in Applied Therapeutics in the 2nd quarter valued at about $87,000. Algert Global LLC acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $110,000. Finally, Intech Investment Management LLC acquired a new position in Applied Therapeutics during the 3rd quarter worth approximately $162,000. Institutional investors and hedge funds own 98.31% of the company's stock.

Applied Therapeutics Price Performance

APLT traded down $0.12 during trading on Thursday, hitting $1.13. The company's stock had a trading volume of 17,294,716 shares, compared to its average volume of 2,534,678. The firm's 50 day moving average price is $7.61 and its 200-day moving average price is $6.29. The stock has a market cap of $130.91 million, a PE ratio of -0.77 and a beta of 1.77. Applied Therapeutics, Inc. has a twelve month low of $1.12 and a twelve month high of $10.62.

Analysts Set New Price Targets

Several brokerages have recently commented on APLT. Citigroup decreased their price target on Applied Therapeutics from $13.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, November 29th. Leerink Partners upped their target price on Applied Therapeutics from $11.00 to $14.00 and gave the company an "outperform" rating in a research note on Thursday, September 19th. Royal Bank of Canada lowered Applied Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $12.00 to $4.00 in a research note on Friday, November 29th. UBS Group reaffirmed a "neutral" rating and issued a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Finally, Robert W. Baird reduced their target price on Applied Therapeutics from $14.00 to $5.00 and set an "outperform" rating on the stock in a research note on Friday, November 29th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.60.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.